How should biotech companies decide between focusing on a single asset or diversifying their portfolio? In this SNiP, Hatch BioFund’s Managing Partner Lorenzo Pellegrini, PhD explores the delicate balance between capital allocation and strategic focus in biotech investment. Drawing on his extensive experience in founding, investing in, and leading biotech organizations, Lorenzo dives into the debate on portfolio diversification, raising critical questions about whether companies should concentrate on a single asset or expand their pipeline—all in under 5 minutes.
From preclinical oncology assets to multi-program portfolios, Lorenzo highlights the risks and rewards of scaling strategically. He emphasizes the importance of crisp go-no-go decisions, careful deployment of capital, and the challenges of assembling top-tier management teams with limited programs.
Tune in to SNiPs on your preferred podcast platform, and contact Bracken to learn more about how we can support biotech companies in navigating complex M&A decisions.